ERYTECH Announces First Patient Enrolled in a Phase 1 Investigator Sponsored Trial of Eryaspase in First-Line Pancreatic Cancer Trial to evaluate safety of eryaspase in combination with FOLFIRINOX for the first-line treatment of pancreatic cancer Trial in Progress (TiP) poster accepted for
ERYTECH to Present at the H.C. Wainwright Virtual BioConnect 2021 Conference Lyon (France) and Cambridge, MA (U.S.), January 6, 2021 – ERYTECH Pharma (Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances
Monthly information related to total number of voting rights and shares composing the share capital – December 31, 2020. Article 223-16 of general regulation of French Autorité des Marchés Financiers Lyon – France
ERYTECH to Present at the LifeSci Partners 10 th Annual Healthcare Corporate Access Event Lyon (France) and Cambridge, MA (U.S.), January 4, 2021 – ERYTECH Pharma (Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug
A total of 510 patients enrolled Events required to trigger interim superiority analysis accrued Interim superiority analysis expected in Q1 2021; final analysis in Q4 2021 LYON, France and CAMBRIDGE, Mass., Dec. 14, 2020 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Nasdaq & Euronext: ERYP), a
LYON, France and CAMBRIDGE, Mass., Dec. 10, 2020 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, announce d today that CEO, Gil Beyen, will
LYON, France, Dec. 10, 2020 (GLOBE NEWSWIRE) -- Article 223-16 of general regulation of French Autorité des Marchés Financiers Lyon – France Listing markets: Euronext Paris from Euronext (Market segment C - ISIN Code: FR0011471135- Symbol: ERYP) & Nasdaq Global Select Market in the United-States
W ebcast today, Monday, December 7 at 4:00 pm CET/10:00 am ET The study confirms the potential of eryaspase as an attractive treatment option for ALL patients with hypersensitivity to PEG-asparaginase LYON, France and CAMBRIDGE, Mass., Dec. 07, 2020 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Nasdaq &
Webcast scheduled for Monday, December 7 at 4:00 pm CET/10:00 am ET LYON, France and CAMBRIDGE, Mass., Dec. 03, 2020 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances
LYON, France and CAMBRIDGE, Mass., Nov. 12, 2020 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Nasdaq & Euronext: ERYP), announced t o day that its CEO, Gil Beyen, will present an update at the Jefferies Virtual London Healthcare Conference at 12 :00 pm EST / 05:00pm GMT / 6 :00 pm CET on November 18, 2020.